Project Overview

P_ERP012611

Limited prolonged effects of rifaximin treatment on irritable bowel syndrome-related differences in the fecal microbiome and metabolome

Visibility: Public
Publication: Limited prolonged effects of rifaximin treatment on irritable bowel syndrome-related differences in the fecal microbiome and metabolome Link
 Journal: Gut Microbes
Source: NA
Sample Number: 175

Samples in this project
  

SampleID Type Habitat Year Sequence type MNS1 MAS2
S_ERP012611.ERR1051033 Gut Feces 2012 16S - -
S_ERP012611.ERR1051034 Gut Feces 2012 16S - -
S_ERP012611.ERR1051035 Gut Feces 2012 16S - -
S_ERP012611.ERR1051036 Gut Feces 2012 16S - -
S_ERP012611.ERR1051037 Gut Feces 2012 16S - -
S_ERP012611.ERR1051038 Gut Feces 2012 16S - -
S_ERP012611.ERR1051039 Gut Feces 2012 16S - -
S_ERP012611.ERR1051040 Gut Feces 2012 16S - -
S_ERP012611.ERR1051041 Gut Feces 2012 16S - -
S_ERP012611.ERR1051042 Gut Feces 2012 16S - -
S_ERP012611.ERR1051043 Gut Feces 2012 16S - -
S_ERP012611.ERR1051044 Gut Feces 2012 16S - -
S_ERP012611.ERR1051045 Gut Feces 2012 16S - -
S_ERP012611.ERR1051046 Gut Feces 2012 16S - -
S_ERP012611.ERR1051047 Gut Feces 2012 16S - -
S_ERP012611.ERR1051048 Gut Feces 2012 16S - -
S_ERP012611.ERR1051049 Gut Feces 2012 16S - -
S_ERP012611.ERR1051050 Gut Feces 2012 16S - -
S_ERP012611.ERR1051051 Gut Feces 2012 16S - -
S_ERP012611.ERR1051052 Gut Feces 2012 16S - -

1MNS (Microbiome Novelty Score): < 0.12: Non-novel; 0.12-0.2: Novel; > 0.2: Very novel; -: NA for samples before 2010

2MAS (Microbiome Attention Score): < 10: Low-attention; ≥ 10: High-attention; -: NA for samples before 2010